BMN 111 (vosoritide) for Achondroplasia, a genetic condition causing short-limbed dwarfism
BioMarin Pharmaceutical· BMN 111 Achondroplasia Phase 3 Study
Reviewed by Blane Jackson, DDS, MBA. Educational analysis only. Read the editorial policy and disclosures.
NCT03197766 on ClinicalTrials.gov →Study type
interventional
Design
Randomized, double-blind, plac…
Target enrollment
121
Est. completion
2019-10-30
Investor scorecard
Probability of success
high
Timeline to catalyst
Historical: this pivotal trial completed in 2019, topline data was positive, and the FDA approved vosoritide as Voxzogo in November 2021. There is no pending catalyst from this study; current BioMarin catalysts center on Voxzogo label expansion in younger children and commercial uptake.
Potential stock impact
transformativeThe Phase 2 data showed a clear dose-response and a meaningful improvement in growth velocity. The mechanism is well-understood, and the drug has a favorable safety profile. The Phase 3 trial was well-designed with a primary endpoint that is clinically relevant. Given the unmet need and regulatory support (Breakthrough Therapy), the probability of success is high, likely above 70%.
What is being tested?
This trial is testing a drug called BMN 111 (also known as vosoritide) in children with achondroplasia, the most common form of dwarfism. Achondroplasia is caused by a genetic mutation that overactivates a signaling pathway, which slows bone growth. BMN 111 is a synthetic version of a natural protein called C-type natriuretic peptide (CNP) that acts as a brake on this pathway, potentially allowing bones to grow more normally. The drug is given as a daily injection under the skin. The goal is to increase the rate of growth in height, improving the final height and body proportions of children with this condition.
How does the trial work?
This was a Phase 3, randomized, double-blind, placebo-controlled study. Children with achondroplasia, aged 5 to 18, were randomly assigned to receive either BMN 111 or a placebo injection daily for 52 weeks. Neither the children, their families, nor the study staff knew which treatment they were getting. The children visited the clinic regularly for measurements of height, body proportions, and safety checks. The main question was whether children receiving BMN 111 would grow faster (in terms of annualized growth velocity) compared to those on placebo. After the 52-week period, all children had the option to continue in an open-label extension where everyone receives the active drug.
What does success look like?
Success would be a statistically significant and clinically meaningful increase in annualized growth velocity at week 52 compared to placebo. For context, children with achondroplasia typically grow about 4-5 cm per year. A meaningful improvement might be an additional 1-2 cm per year. The trial also looked at height Z-score, which compares a child's height to the average for their age and sex; a positive change would indicate improvement. Body proportions (upper to lower segment ratio) were also assessed, as achondroplasia is characterized by a disproportionately short trunk and limbs. Safety was paramount; any serious side effects would be a concern. The FDA has previously indicated that a 1.5 cm/year difference in growth velocity could be considered clinically meaningful.
What it means for investors
For BioMarin, this trial was a pivotal Phase 3 study. Positive results would likely lead to regulatory submissions and potential approval, opening a new market with no approved treatments for achondroplasia. The drug could become a standard of care, generating significant revenue. If the trial failed, it would be a major setback, potentially wiping out billions in market value and forcing the company to abandon the program. Given the unmet need and the drug's mechanism, success could be transformative for BioMarin, establishing a new franchise. However, the market size is relatively small (estimated 250,000 people worldwide), but with high pricing potential, it could still be lucrative. Investors would watch for the magnitude of effect and safety profile to gauge commercial viability.
Trial endpoints
Primary endpoints
Secondary endpoints
Comparator
Placebo (inactive treatment)
Competitive landscape
Achondroplasia is the most common form of skeletal dysplasia, affecting approximately 1 in 25,000 births. The global prevalence is estimated at around 250,000 individuals. There is currently no approved drug therapy; treatment is primarily supportive (surgery for spinal stenosis, etc.). A disease-modifying therapy could address the underlying growth deficit, potentially improving quality of life and reducing complications. The market potential is significant given the lack of competition and the chronic nature of the condition. Pricing could be high, similar to other rare disease drugs, potentially exceeding $100,000 per year. With a patient population that is diagnosed early, a successful drug could capture a large share of the eligible patients.
| Drug | Sponsor | Phase | Differentiation |
|---|---|---|---|
| TransCon CNP (palopegteriparatide) | Ascendis Pharma | Phase 1 | Long-acting prodrug of CNP, administered once weekly, potentially more convenient than daily injections. |
| Infigratinib (BGJ398) | QED Therapeutics (BridgeBio) | Phase 1 | Oral FGFR3 inhibitor, targets the underlying receptor, but has safety concerns (hyperphosphatemia). |
| Recifercept (TA-46) | Therachon (acquired by Pfizer) | Phase 1 | Soluble FGFR3 decoy, binds to FGF ligands, but development was discontinued due to lack of efficacy. |
Historical context
Prior trial results
In Phase 2 studies, vosoritide showed a dose-dependent increase in growth velocity. A 24-month open-label extension demonstrated sustained improvement in growth, with a mean increase of 1.5 cm/year compared to baseline. The drug was generally well-tolerated, with injection site reactions being the most common adverse event.
Regulatory history
Vosoritide received Orphan Drug Designation from the FDA and EMA. It also received Breakthrough Therapy Designation from the FDA in 2019 based on Phase 2 data. No complete response letters or clinical holds have been issued.
Similar drug precedents
There are no approved drugs for achondroplasia, but the precedent of growth hormone (somatropin) for growth hormone deficiency shows that a growth-promoting therapy can be successful commercially. However, growth hormone has not been approved for achondroplasia due to limited efficacy. The success of enzyme replacement therapies for other rare genetic disorders (e.g., Fabrazyme for Fabry disease) demonstrates the viability of chronic protein replacement therapies.